Diagnostic Imaging and Management of Portal Vein and Superior Mesenteric Vein Thrombosis

Introduction to Diagnostic Tests

Contrast-enhanced CT angiography (CTA) with arterial and venous phases is the gold standard diagnostic test for evaluating portal vein and superior mesenteric vein thrombosis, offering the highest sensitivity and specificity, as recommended by the American Association for the Study of Liver Diseases 1

The following imaging modalities are recommended for diagnosis:

Imaging Modality	Characteristics	Recommendations
Doppler Ultrasonography	High sensitivity, non-invasive, wide availability	First-line imaging modality, as supported by the National Comprehensive Cancer Network and the European Association for the Study of the Liver [1, 2]
CT Angiography	Better visualization of the extent of thrombosis, assessment of mesenteric veins and branches	Preferred second-line imaging modality, especially for mesenteric vein involvement, as recommended by the Journal of Hepatology and the American College of Radiology [1, 2]
MR Venography	No radiation exposure, useful when biliary complications are suspected	Alternative second-line option, as recommended by the Journal of the National Comprehensive Cancer Network and the European Society of Radiology [2, 1]

Acute thrombosis indicators include symptoms present for ≤8 weeks, spontaneous hyperdense clot on non-enhanced CT, as recommended by the American College of Gastroenterology 1
Chronic thrombosis indicators include symptoms present for >8 weeks, presence of portal cavernoma (collateral vessels), and cavernoma may develop as early as 15-30 days after symptom onset, as described by the European Association for the Study of the Liver 1
Key findings on CT angiography include portal vein filling defect or absence of visible lumen, extent of thrombus into mesenteric veins, and "target sign" in SMV thrombosis, as described by the American Roentgen Ray Society 3, 4
Doppler ultrasonography can show absence of flow in portal vein, flow velocity <30 cm/s, dilated left and short gastric veins, portosystemic collaterals, and reversal of portal flow direction, and is recommended as the first-line imaging modality by the National Comprehensive Cancer Network and the European Association for the Study of the Liver 2, 1, 5

Each 24-hour delay in diagnosis doubles mortality, emphasizing the need for prompt diagnosis and treatment, as stated by the World Health Organization 4
Early diagnosis is crucial to prevent complications like variceal bleeding and intestinal ischemia, and the American Association for the Study of Liver Diseases recommends that Doppler ultrasonography is used to differentiate portal hypertension from portal venous thrombosis, with characteristic findings guiding management decisions, including portosystemic collaterals and reversal of portal flow direction 6
The American College of Radiology and the European Association for the Study of the Liver recommend measuring hepatic venous pressure gradient (HVPG) to confirm clinically significant portal hypertension, with HVPG ≥10 mmHg confirming the diagnosis, and HVPG >16 mmHg indicating higher mortality risk 6, 7

The American College of Gastroenterology recommends non-selective beta-blockers for primary/secondary prophylaxis of variceal bleeding, and diuretics for ascites management, in patients with portal hypertension, with medical management tailored to the individual patient's needs and regular follow-up and monitoring, as recommended by the American Association for the Study of Liver Diseases 8
Immediate anticoagulation is critical to prevent extension and promote recanalization in acute symptomatic portal vein thrombosis (PVT), with low-molecular-weight heparin (LMWH) preferred over unfractionated heparin, started at therapeutic doses (e.g., enoxaparin 1 mg/kg twice daily), and continued for at least 6 months, as recommended by the American College of Chest Physicians and 1, 9

The Society of Interventional Radiology recommends considering Transjugular Intrahepatic Portosystemic Shunt (TIPS) for refractory ascites or recurrent variceal bleeding, with regular post-TIPS ultrasound monitoring (every 6 months), and evaluating TIPS dysfunction with abnormal flow velocities and altered intrahepatic portal vein flow direction indicating the need for further intervention, as suggested by the American College of Radiology 10, 8
Consider TIPS (transjugular intrahepatic portosystemic shunt) for failed anticoagulation, complete/extensive thrombosis, or symptomatic portal hypertension, as recommended by the American College of Radiology 11
Portal vein recanalization and stenting should be considered for non-cirrhotic patients with occlusion limited to main portal vein and first-order branches, as recommended by 11

Follow-up imaging should be performed at 6-12 months to assess recanalization, and in pediatric patients, screening should start at 6 months after the event, then annually for 5 years, as recommended by the Journal of Thrombosis and Haemostasis and the International Society on Thrombosis and Haemostasis, and CT scan should be performed to assess recanalisation of the portal venous system at 6-12 months, and screen for gastroesophageal varices in unrecanalised patients, as recommended by the American Association for the Study of Liver Diseases 12, 1